According to Junshi Biotech's announcement, the company's product treprilizumab injection combined with viducitumab for use in locally advanced or metastatic urothelial cancer expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. The new medical insurance catalogue will be officially implemented on January 1, 2027, and the agreement is valid from January 1, 2027 to December 31, 2027. As of the announcement disclosure date, all 13 indications approved for marketing by Tuoyi® in mainland China have been included in the national health insurance catalogue.

Zhitongcaijing · 2d ago
According to Junshi Biotech's announcement, the company's product treprilizumab injection combined with viducitumab for use in locally advanced or metastatic urothelial cancer expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. The new medical insurance catalogue will be officially implemented on January 1, 2027, and the agreement is valid from January 1, 2027 to December 31, 2027. As of the announcement disclosure date, all 13 indications approved for marketing by Tuoyi® in mainland China have been included in the national health insurance catalogue.